Zobrazeno 1 - 10
of 62
pro vyhledávání: ''
Autor:
Isamu Okamoto, Yuichi Takiguchi, Nobuyuki Yamamoto, Ichiro Yoshino, Takehito Shukuya, Etsuo Miyaoka, Koichi Takayama, Kazuhisa Takahashi, Yasushi Shintani, Meinoshin Okumura, Katsuhiko Naoki, Satoshi Igawa, Ikuo Sekine, Katsuyuki Kiura, Akira Inoue
Publikováno v:
Lung Cancer. 146:160-164
Objectives Most patients with small-cell lung cancer (SCLC) experience relapse because of the emergence of drug-resistant tumor cells. Therefore, second-line therapy is subsequently required to prolong their survival. However, it is unclear whether s
Autor:
Anas Gazzah, Pilar Garrido, Alexis B. Cortot, Jaafar Bennouna, Melissa Lynne Johnson, Maciej Gil, Haruyasu Murakami, Benjamin Besse
Publikováno v:
Lung Cancer. 142:63-69
Objectives Efficacy and safety of necitumumab when combined with pembrolizumab was assessed in patients with Stage IV non-small cell lung cancer (NSCLC) of squamous and nonsquamous histology, who had progressed after treatment with a platinum-based d
Autor:
Takashi Seto, Noboru Yamamoto, Takeharu Yamanaka, Yuichiro Ohe, Makoto Nishio, Tatsuya Yoshida, Toyoaki Hida, Akira Ono, Takayasu Kurata, Kentaro Sakamaki, Hiroaki Okamoto, Miyako Satouchi, Seiji Niho, Koichi Goto, Tetsuo Akimoto
Publikováno v:
Lung Cancer. 141:64-71
Objectives SPECTRA is a multicenter, randomized phase II study of chemotherapy with cisplatin (CDDP) plus S-1 versus CDDP plus pemetrexed (PEM) in combination with thoracic radiotherapy (TRT) for locally advanced non-squamous non-small cell lung canc
Autor:
Alvin Soon Tiong Lim, Quan Sing Ng, Anantham Devanand, Daniel S.W. Tan, T. Rajasekaran, Eng Huat Tan, Zaw Win Aung, Chee Keong Toh, G. Lai, Chow Wei Too, Tony Kiat-Hon Lim, Aaron C. Tan, Bien Soo Tan, Tina P.T. Koh, Tse Hui Lim, Mei-Kim Ang, Angela Takano, Wan Ling Tan, Shou Yu Poon, Brett Doble, Apoorva Gogna, Amit Jain, Boon-Hean Ong, Ravindran Kanesvaran, Wan-Teck Lim, Gek San Tan
Publikováno v:
Lung Cancer. 139:207-215
Objectives There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling traditional single biomarker assays from small biopsie
Publikováno v:
Lung Cancer. 138:52-57
Brain metastasis (BM) is common in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer. However, the brain surveillance strategy during treatment in advanced lung cancer patients varies, and the impact on clinical outcome is uncl
Autor:
Masaru Suzuki, Satoshi Oizumi, Eiki Kikuchi, Kenya Kanazawa, Hisashi Tanaka, Kaoruko Shimizu, Hiroshi Yokouchi, Ryoichi Honda, Toshiyuki Harada, Hajime Asahina, Tomoo Ikari, Kei Takamura, Tetsuya Kojima, Masao Harada, Yuka Fujita, Hiroshi Isobe, Hirotoshi Dosaka-Akita, Takahiro Ogi, Masaharu Nishimura, Fumiko Sugaya, Satoshi Konno
Publikováno v:
Lung cancer. 138:65-71
Objectives Patients with concomitant advanced non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD) are excluded from most clinical chemotherapy trials because of the high risk of exacerbating the latter condition. This study prospec
Autor:
Primo N. Lara, M. Phillip DeYoung, Xiaowei Wang, Sergey Orlov, Enriqueta Felip, James Vasquez, Katherine Baker-Neblett, Manuel Domine, Nina Karaseva, Ulrik Lassen, Li Yan, Daniel Morgensztern, Pilar Garrido, Jose Manuel Trigo, Paul K. Paik, Marina Shomova, Ionel Mitrica, Ignacio Delgado, Olga Burdaeva
Publikováno v:
Lung Cancer. 136:74-79
Objectives GSK3052230 (FP-1039) is a soluble fusion protein that acts as ligand trap sequestering fibroblast growth factors (FGFs) involved in tumor growth and angiogenesis, while sparing the hormonal FGFs. Because of this selectivity, the molecule i
Autor:
Konstantinos N. Syrigos, Mark A. Socinski, Wei Zhang, Dimitrios Mavroudis, Liza C. Villaruz, Jong Seok Kim, Manuel Cobo
Publikováno v:
Lung Cancer. 136:52-56
Objectives Necitumumab is a second-generation, recombinant, human IgG1-type monoclonal antibody directed against EGFR approved for adult patients with metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplati
Autor:
Santiago Viteri, Santiago Ramón y Cajal, José Ignacio Toscas, Irene Moya-Horno, José Antonio Maestre-Alcácer, Rafael Rosell, Laura Romero-Vielva
Publikováno v:
Lung Cancer. 133:117-122
Introduction Despite all treatment advances, lung cancer is still the main cause of death worldwide. Treatment for resectable stage IIIA remains controversial including definitive chemoradiotherapy and induction treatment followed by surgery. After d
Publikováno v:
Lung Cancer. 133:103-109
Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used as first-line standard treatment for advanced lung adenocarcinoma with mutant EGFR. Nevertheless, few studies have demonstrated the efficacy of first- and s